ASSOCIATION BETWEEN INTRAVESICAL IMMUNOTHERAPY AND ANTINEOPLASTIC CHEMOTHERAPY IN TREATMENT OF THE UROTHELIAL CARCINOMA OF THE URINARY BLADDER IN DOG
Keywords:
BCG, urothelial carcinoma, urinary bladder, dogAbstract
O carcinoma urotelial, embora de ocorrência rara, é a neoplasia mais comum da vesícula urinária de cães. A terapia intravesical com o Bacilo de Calmette-Guérin, BCG é utilizada em carcinomas vesicais humanos com boa resposta, porém é pouco descrita em cães. O presente trabalho relata o caso de uma cadela, sem raça definida, com 10 anos de idade, portadora de carcinoma urotelial em vesícula urinária tratada com associação de quimioterapia antineoplásica, inibidor de COX-2 e BCG intravesical. O uso da imunoterapia proporcionou resultados satisfatórios, pois, enquanto administrado na paciente, interrompeu a progressão tumoral e o desenvolvimento de metástases. Trata-se, portanto, de uma modalidade promissora no controle de neoplasias.
References
Norris AM, Laing EJ, Valli VE, Withrow SJ, Macy DW, Ogilvie GK, et al. Canine bladder and urethral tumors: a retrospective study of 115 cases (1980–1985). J Vet Intern Med. 1992;6:145–53.
Inkelmann MA, Kommers GD, Fighera RA, Irigoyen LF, Barros CSL, Silveira IP, et al. Neoplasmas do sistema urinário em 113 cães. Pesq Vet Bras. 2011;31:1102-7.
Knapp DW. Tumors of the urinary system. In: Withrow SJ, Vail DM. Withrow and MacEwen’s Small Animal Clinical Oncology. 4a ed. Philadelphia: WB Saunders, 2007. p.649–59
Henry CJ. Management of transitional cell carcinoma. Vet Clin North Am Small Anim Pract. 2003;33:597–613.
Mutsaers AJ, Widmer WR, Knapp DW. Canine transitional cell carcinoma. J Vet Intern Med. 2003;17:136-44.
Knapp DW, Glickman NW, Denicola DB, Bonney PL, Lin TL, Glickman LT. Naturally occurring canine transitional cell carcinoma of the urinary bladder. A relevant model of human invasive bladder cancer. Urol Oncol. 2000;5:47–9.
Carvalho MB, Brum AM. Neoplasias do sistema urinário. In: Daleck CR, De Nardi AB, Rodaski S. Oncologia em cães e gatos. São Paulo: Roca, 2009. p.386-98.
Jancke G, Rosell J, Chebil G, Jahnson S. Bladder wash cytology at diagnosis of ta-t1 bladder cancer is predictive for recurrence and progression. Urology. 2012;80:625-31.
Jark PC, Machado LHA, Lourenço MLG, Sakate M. Uso de inibidores de COX-2 no tratamento do carcinoma de células de transição de bexiga em cães: revisão. Vet e Zootec. 2011;18:523-30.
Caswell M. Transitional cell carcinoma of the urinary bladder in a 14-year-old dog. Can Vet J. 2011;52:673-5.
Askeland EJ, Newton MR, O’Donnell MA, Luo Y. Bladder Cancer Immunotherapy: BCG and Beyond. Adv Urol. 2012;2012:1-13.
Molnár T, Vajdovich P. Clinical factors determining the efficacy of urinary bladder tumour treatments in dogs: surgery, chemotherapy or both? Acta Vet Hung. 2012;60:55-68.
Tamás M, Péter V. Clinical factors determining the efficacy of urinary bladder tumour treatments in dogs: surgery, chemotherapy or both? Acta Vet Hung. 2012; 60:55-68.
Mutsaers AJ, Mohammed DB, Denicola DB, Snyder PW, Glickman PF, Bennett PF, et al. Pretreatment tumor prostaglandin E2 concentration and cyclooxygenase-2 expression are not associated with the response of canine naturally occurring invasive urinary bladder cancer to cyclooxygenase inhibitor therapy. Prostaglandins Leukot Essent Fatty Acids. 2005; 72:181-6.
Downloads
Published
How to Cite
Issue
Section
License
Este obra está licenciado com uma Licença Creative Commons Atribuição-NãoComercial 4.0 Internacional.
